{"id":"placebo-of-mp-513","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4594369","moleculeType":"Small molecule","molecularWeight":"345.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo formulation, it is pharmacologically inert and serves as a control comparator in clinical trials. It is used to establish the baseline effect and safety profile against which the active drug MP-513 is evaluated.","oneSentence":"This is a placebo control and contains no active pharmaceutical ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:35.343Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00971243","phase":"PHASE2","title":"Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":448},{"nctId":"NCT02354235","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT02354222","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT01026194","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":204},{"nctId":"NCT00628212","phase":"PHASE2","title":"Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT00998881","phase":"PHASE3","title":"Monotherapy Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":203},{"nctId":"NCT02081599","phase":"PHASE4","title":"Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-01","conditions":"Type 2 Diabetes Mellitus","enrollment":148},{"nctId":"NCT01072331","phase":"PHASE3","title":"Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus","enrollment":99},{"nctId":"NCT01805830","phase":"PHASE3","title":"Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2012-05","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT01798238","phase":"PHASE3","title":"Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2012-11","conditions":"Type 2 Diabetes Mellitus","enrollment":142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of MP-513","genericName":"Placebo of MP-513","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}